Shenzhen Edge Medical priced an HKEX IPO to raise roughly US$154 million to expand its surgical robotics lineup and pursue international markets. The listing follows a busy year for med‑tech exits and signals investor appetite for robotics. In the U.S., FDA clearances of Medtronic’s Hugo and CMR Surgical’s Versius Plus add new soft‑tissue robotics choices for hospitals, increasing competition for Intuitive and pressuring procurement strategies across health systems.